Clinical Trials Logo
  1. Home
  2. Meningioma
  3. NCT06255249

Multicenter Evaluation in Patients With MEningiomas of the Response to Treatment With 177LUTEtium-oxodotreotide — MELUTE  

Meningioma Clinical Trial

Official title:
Multicenter Evaluation in Patients With MEningiomas Expressing Somatostatin Type 2 Receptors and After Failure of Standard Treatments, of the Response to Treatment With 177LUTEtium-oxodotreotide

Clinical Trial Summary

Meningiomas are the most common primary tumors of the central nervous system, representing more than a third of tumors.Current conventional treatments for meningioma are surgery and radiotherapy. When these treatments are no longer feasible, meningiomas are considered refractory regardless of their grade. Some meningiomas express somatostatin type 2 receptors and can be treated with lutathera. This study aims to evaluate the response to treatment in this pathology

Clinical Trial Description

In nuclear medicine, peptide receptor radionuclide therapy with 177Lu-oxodotreotide, deploys an octreotide-like effect and appears very promising, with a preliminary progression free survival at 6 months of 94% and overall survival at 12 months of 88% in grade 1 meningiomas, and 28% with an overall survival at 12 months of 65% in grades 2 and 3 meningiomas. These results are nevertheless the result of a meta-analysis obtained from series of patients limited in number and heterogeneous in terms of type of treatment modality. At the request of healthcare professionals and in consultation with the Advanced Accelerator Applications laboratory, the Agency of the drug security has developed a compassionate prescribing framework aimed at securing the use of Lutathera in meningiomas of all grades, expressing type 2 somatostatin in imaging of nuclear medicine, after failure of the standard treatment (surgery, radiotherapy/radio-surgery) or impossibility of carrying it out (multiple lesions, inaccessible lesions), at the suggestion of the national comitee OMEGA (April 6, 2022). This cohort has the advantage of being consistent and homogeneous in terms of type of treatment and method of administration. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06255249
Study type Observational
Source Central Hospital, Nancy, France
Contact CAROLINE BOURSIER, MD
Phone 0383154039
Email c.boursieur@chru-nancy.fr
Status Not yet recruiting
Phase
Start date March 30, 2024
Completion date June 30, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04081701 - 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors. Phase 4
Recruiting NCT03631953 - Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas Phase 1
Completed NCT03273712 - Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) Phase 2
Recruiting NCT04367779 - Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
Withdrawn NCT00985036 - Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients N/A
Completed NCT01347307 - Stereotactic Body Radiotherapy for Spine Tumors N/A
Completed NCT01811524 - The Etiology and Progression of Brain Tumors N/A
Completed NCT03648034 - Effects of Scalp Nerve Block With Ropivacaine on Postoperative Recovery Quality N/A
Recruiting NCT06036706 - Neurocognitive Impact of Different Irradiation Modalities for Patients With Grade I-II Skull Base Meningioma: N/A
Recruiting NCT06014905 - Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma Phase 1
Not yet recruiting NCT04386642 - Tranexamic Acid Reduce Blood Loss in Meningioma Resection Phase 4
Active, not recruiting NCT04595786 - The Safety of Intravenous Tranexamic Acid in Patients Undergoing Supratentorial Meningiomas Resection N/A
Active, not recruiting NCT04305470 - Gleolan for Visualization of Newly Diagnosed or Recurrent Meningioma Phase 3
Completed NCT01967823 - T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer Phase 2
Not yet recruiting NCT02978677 - Proton Dose Escalation for Patients With Atypical or Anaplastic Meningiomas N/A
Active, not recruiting NCT02933736 - Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients Early Phase 1
Completed NCT02267928 - Information Presentation Formats N/A
Completed NCT00589784 - Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Phase 2
Active, not recruiting NCT03071874 - Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas Phase 2
Recruiting NCT05416567 - Embolization for Meningioma N/A